Sign up USA
Proactive Investors - Run By Investors For Investors

Former Callitas Health CEO Gary Thompson passes away after battle with cancer

James Thompson took over the reins of the Cincinnati-based health and wellness company from his uncle earlier this year
Gary Thompson
Former Callitas Health CEO Gary Thompson was very well regarded in the pharmaceutical industry

Cincinnati-based health and wellness company Callitas Health Inc (CSE:LILY, OTCQB:MPHMF, OTCMKTS: MPHMF) announced Friday that former CEO Gary A Thompson died after a long battle with cancer.

Thompson, who died Tuesday, was a pharmaceutical industry veteran with a career spanning over three decades. He worked with pharmaceutical giants and startups. He served as vice president of sales for Cigna Healthcare (NYSE:CI) before taking over the reins of M Pharmaceutical Inc and later Callitas Health. Thompson was a graduate of Northern Kentucky University, with a BS in Kinesiology.

Callitas Health CEO James Thompson, took over the mantle from his uncle, Gary, earlier this year.

“Gary was a larger-than-life figure who brought his remarkable passion, experience and energy to Callitas Health and he will be greatly missed,” said Callitas Board member William Rodgers.

Callitas Health, which is now spearheaded by the second generation of Thompsons, is a well-diversified company. It has a nimble strategy focused on getting quick revenues from mass-appeal over-the-counter products and a more long-term blockbuster pipeline. It is active across five silos: OTC sexual health & wellness, prescriptions for female sexual health, weight management, cannabis delivery technologies and orphan drugs.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full LILY profile View Profile

Callitas Health Inc. Timeline

Related Articles

mountains
August 22 2018
So far, the hit rate is a five out of 12 success rate for its investments
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
bacteria
Tue
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use